In past decades, anticancer research has led to remarkable results despite many of the
approved drugs still being characterized by high systemic toxicity mainly due to the lack of …

Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-
term survival rates now exceeding 90% after treatment with chemotherapy alone or …

Background Children and adolescents with intermediate-stage and advanced-stage
classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after …

Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study,
was designed to evaluate the role of early chemotherapy response in tailoring subsequent …

In high-income countries (HICs), the annual incidence of childhood cancer is approximately
140 per 1 million children younger than age 15 years, although estimates vary between and …

The majority of children, adolescents, and young adults diagnosed with cancer will become
long-term survivors. Although cancer therapy is associated with many adverse effects, one of …

Purpose To minimize the risk of late effects in pediatric Hodgkin lymphoma (HL) by omitting
radiotherapy (RT) in patients in complete remission (CR) after chemotherapy and reducing …

Background A high proportion of patients with relapsed classical Hodgkin's lymphoma
achieve a response with the antibody-drug conjugate brentuximab vedotin, and the drug is …

BACKGROUND Owing to a growing number of young and adolescent Hodgkin lymphoma
(HL) survivors, awareness of (long-term) adverse effects of anticancer treatment increases …

PURPOSE Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved
for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial …